Public Companies
Small Pharma Announces Additional Positive Data From Phase 2a Trial
The article Small Pharma Announces Additional Positive Data From Phase 2a Trial was originally published on Microdose.
Back in end-January, we reported…
The article Small Pharma Announces Additional Positive Data From Phase 2a Trial was originally published on Microdose.
Back in end-January, we reported on Small Pharma’s positive results for its Phase 2a trial using DMT-assisted therapy to treat Major Depressive Disorder. 3 months after a single dose of DMT — paired with preparation and integration therapy — 57% of depression patients were considered to be in remission.
These were very encouraging results, backing up the thesis that faster-acting psychedelics like DMT could provide significant healing potential in a much shorter period.
Today, both patients and investors received additional good news, as Small Pharma has reported supportive data to corroborate its initial Phase 2 trial topline results.
Analyses of additional secondary and exploratory endpoints, including effects on self-reported depression, anxiety and wellbeing, demonstrated that patients receiving at least a single dose of IV SPL026 with supportive therapy experienced clinically relevant improvements in function and mood, further supporting previously announced topline efficacy results.
Patients’ self-reported depression and well-being scores that matched previous topline MADRS efficacy data. There was also statistically significant improvement in anxiety symptoms, which could offer potential new indications for the medicine beyond depression.
See below for our chat with EF Hutton analyst about Small Pharma’s program and read the full press release below.
dmt psychedelic therapy major depressive disorder depressive disorder depression anxiety psychedelics investors small pharma
-
Psilocybin1 week ago
Are Shrooms Legal in Oregon: Full Guide
-
Psychedelics1 week ago
Atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology
-
Law & Regulation1 week ago
Clearmind signs agreement with Hebrew University for psychedelic compound rights
-
Psilocybin1 week ago
California advances bill for psychedelics centers
-
Psychedelics1 week ago
Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry
-
Psychedelics1 week ago
Revive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product
-
Psychedelics1 week ago
Psychedelics Can Offer More Than Therapy On Its Own
-
Psilocybin3 days ago
Passover Perspectives: Psychedelics, Moses, and the Burning Bush